358 related articles for article (PubMed ID: 35144648)
41. Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy.
Grywalska E; Sosnowska-Pasiarska B; Smok-Kalwat J; Pasiarski M; Niedźwiedzka-Rystwej P; Roliński J
Cells; 2020 Apr; 9(4):. PubMed ID: 32316105
[TBL] [Abstract][Full Text] [Related]
42. Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity.
Globerson Levin A; Rawet Slobodkin M; Waks T; Horn G; Ninio-Many L; Deshet Unger N; Ohayon Y; Suliman S; Cohen Y; Tartakovsky B; Naparstek E; Avivi I; Eshhar Z
Cancer Immunol Res; 2020 Dec; 8(12):1485-1495. PubMed ID: 33008840
[TBL] [Abstract][Full Text] [Related]
43. Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-κB signaling in vivo.
Xiao X; Ma Z; Li Z; Deng Y; Zhang Y; Xiang R; Zhu L; He Y; Li H; Jiang Y; Zhu Y; Xie Y; Peng H; Liu X; Wang H; Ye M; Zhao Y; Liu J
Biomaterials; 2023 Jun; 297():122096. PubMed ID: 37075614
[TBL] [Abstract][Full Text] [Related]
44. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma.
Bu DX; Singh R; Choi EE; Ruella M; Nunez-Cruz S; Mansfield KG; Bennett P; Barton N; Wu Q; Zhang J; Wang Y; Wei L; Cogan S; Ezell T; Joshi S; Latimer KJ; Granda B; Tschantz WR; Young RM; Huet HA; Richardson CJ; Milone MC
Oncotarget; 2018 May; 9(40):25764-25780. PubMed ID: 29899820
[TBL] [Abstract][Full Text] [Related]
45. Antibody targeting of B-cell maturation antigen on malignant plasma cells.
Ryan MC; Hering M; Peckham D; McDonagh CF; Brown L; Kim KM; Meyer DL; Zabinski RF; Grewal IS; Carter PJ
Mol Cancer Ther; 2007 Nov; 6(11):3009-18. PubMed ID: 18025285
[TBL] [Abstract][Full Text] [Related]
46. Comprehensive BCMA Expression Profiling in Adult Normal Human Brain Suggests a Low Risk of On-target Neurotoxicity in BCMA-targeting Multiple Myeloma Therapy.
Marella M; Yao X; Carreira V; Bustamante MF; Clark HB; Jackson CC; Zudaire E; Schecter JM; Glover TD; Shenton J; Cornax I
J Histochem Cytochem; 2022 Apr; 70(4):273-287. PubMed ID: 35193424
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
Front Immunol; 2021; 12():720571. PubMed ID: 34421924
[TBL] [Abstract][Full Text] [Related]
48. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker.
Sanchez E; Tanenbaum EJ; Patil S; Li M; Soof CM; Vidisheva A; Waterman GN; Hekmati T; Tang G; Wang CS; Chen H; Berenson J
Expert Rev Mol Diagn; 2018 Apr; 18(4):319-329. PubMed ID: 29504446
[TBL] [Abstract][Full Text] [Related]
49. The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma.
Xu Y; Mao X; Que Y; Xu M; Li C; Almeida VDF; Wang D; Li C
BMC Cancer; 2023 Feb; 23(1):123. PubMed ID: 36750969
[TBL] [Abstract][Full Text] [Related]
50. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J
Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480
[TBL] [Abstract][Full Text] [Related]
51. B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives.
Sellner L; Fan F; Giesen N; Schubert ML; Goldschmidt H; Müller-Tidow C; Dreger P; Raab MS; Schmitt M
Int J Cancer; 2020 Oct; 147(8):2029-2041. PubMed ID: 32270481
[TBL] [Abstract][Full Text] [Related]
52. Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways.
Shen X; Guo Y; Qi J; Shi W; Wu X; Ju S
Cell Biochem Funct; 2016 Mar; 34(2):104-10. PubMed ID: 26914861
[TBL] [Abstract][Full Text] [Related]
53. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
Lin L; Cho SF; Xing L; Wen K; Li Y; Yu T; Hsieh PA; Chen H; Kurtoglu M; Zhang Y; Andrew Stewart C; Munshi N; Anderson KC; Tai YT
Leukemia; 2021 Mar; 35(3):752-763. PubMed ID: 32632095
[TBL] [Abstract][Full Text] [Related]
54. BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.
Cho SF; Lin L; Xing L; Li Y; Yu T; Anderson KC; Tai YT
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32516895
[TBL] [Abstract][Full Text] [Related]
55. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
[TBL] [Abstract][Full Text] [Related]
56. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.
Roex G; Timmers M; Wouters K; Campillo-Davo D; Flumens D; Schroyens W; Chu Y; Berneman ZN; Lion E; Luo F; Anguille S
J Hematol Oncol; 2020 Dec; 13(1):164. PubMed ID: 33272302
[TBL] [Abstract][Full Text] [Related]
57. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.
Chen H; Li M; Xu N; Ng N; Sanchez E; Soof CM; Patil S; Udd K; Bujarski S; Cao J; Hekmati T; Ghermezi M; Zhou M; Wang EY; Tanenbaum EJ; Zahab B; Schlossberg R; Yashar MA; Wang CS; Tang GY; Spektor TM; Berenson JR
Leuk Res; 2019 Jun; 81():62-66. PubMed ID: 31035033
[TBL] [Abstract][Full Text] [Related]
58. B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma.
Eckhert E; Hewitt R; Liedtke M
Immunotherapy; 2019 Jun; 11(9):801-811. PubMed ID: 31094254
[TBL] [Abstract][Full Text] [Related]
59. Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma.
Jasiński M; Basak GW; Jedrzejczak WW
Front Immunol; 2021; 12():632937. PubMed ID: 33717171
[TBL] [Abstract][Full Text] [Related]
60. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.
Da Vià MC; Dietrich O; Truger M; Arampatzi P; Duell J; Heidemeier A; Zhou X; Danhof S; Kraus S; Chatterjee M; Meggendorfer M; Twardziok S; Goebeler ME; Topp MS; Hudecek M; Prommersberger S; Hege K; Kaiser S; Fuhr V; Weinhold N; Rosenwald A; Erhard F; Haferlach C; Einsele H; Kortüm KM; Saliba AE; Rasche L
Nat Med; 2021 Apr; 27(4):616-619. PubMed ID: 33619368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
